Clinical implications emphasize mirvetuximab soravtansine’s pivotal role in targeted therapy, especially for high FRα-expressing tumors, potentially reshaping platinum-resistant ovarian cancer management. The gene discussed is FOLR1; the disease is ovarian cancer.